OBJECTIVES: Interleukin-10 (IL-10) has been implicated in immune deficiency in patients with cancer. The relationship of this cytokine as measured in serum to anti-tumor immunity and prognosis was investigated in unresectable hepatocellular carcinoma. METHODS: This study consisted of 74 consecutive patients with unresectable hepatocellular carcinoma (median age, 65 years). Forty-four healthy age-matched subjects and 32 patients with cirrhosis but no carcinoma served as controls. Patients with hepatocellular carcinoma were divided into those with serum IL-10 concentrations above (high group, n=39) or below (low group, n=35) 10pg/ml. RESULTS: Age, gender, Child-Pugh grade, and tumor stage distributions were similar in high and low groups. The patients of high group showed lower in lymphokine-activated killer (LAK) and natural killer (NK) activities than those of low group (P<0.01 and 0.01, respectively). Serum IL-10 concentration was a significant factor contributing to low activities of LAK and NK by logistic regression analysis (P<0.05 and 0.05, respectively). The high group had a significantly shorter survival (median, 3 months) than low group (median, 12 months; P<0.02, generalized Wilcoxon test). CONCLUSIONS: These data suggest that serum IL-10 concentration is a possible factor contributing to poor prognosis and low anti-tumor immunity in patients with unresectable hepatocellular carcinoma.
OBJECTIVES:Interleukin-10 (IL-10) has been implicated in immune deficiency in patients with cancer. The relationship of this cytokine as measured in serum to anti-tumor immunity and prognosis was investigated in unresectable hepatocellular carcinoma. METHODS: This study consisted of 74 consecutive patients with unresectable hepatocellular carcinoma (median age, 65 years). Forty-four healthy age-matched subjects and 32 patients with cirrhosis but no carcinoma served as controls. Patients with hepatocellular carcinoma were divided into those with serum IL-10 concentrations above (high group, n=39) or below (low group, n=35) 10pg/ml. RESULTS: Age, gender, Child-Pugh grade, and tumor stage distributions were similar in high and low groups. The patients of high group showed lower in lymphokine-activated killer (LAK) and natural killer (NK) activities than those of low group (P<0.01 and 0.01, respectively). Serum IL-10 concentration was a significant factor contributing to low activities of LAK and NK by logistic regression analysis (P<0.05 and 0.05, respectively). The high group had a significantly shorter survival (median, 3 months) than low group (median, 12 months; P<0.02, generalized Wilcoxon test). CONCLUSIONS: These data suggest that serum IL-10 concentration is a possible factor contributing to poor prognosis and low anti-tumor immunity in patients with unresectable hepatocellular carcinoma.
Authors: Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos Journal: Clin Cancer Res Date: 2013-07-09 Impact factor: 12.531
Authors: Kelly Speiran; Daniel P Bailey; Josephine Fernando; Matthew Macey; Brian Barnstein; Motunrayo Kolawole; Dana Curley; Stephanie S Watowich; Peter J Murray; Carole Oskeritzian; John J Ryan Journal: J Leukoc Biol Date: 2009-02-19 Impact factor: 4.962
Authors: Hala M Hatab; Fatma F Abdel Hamid; Ahmed F Soliman; Tamer A Al-Shafie; Yahia M Ismail; Motawa E El-Houseini Journal: J Gastrointest Oncol Date: 2019-08